BRPI0417406A - anticorpo do receptor anti-igf-i - Google Patents
anticorpo do receptor anti-igf-iInfo
- Publication number
- BRPI0417406A BRPI0417406A BRPI0417406-2A BRPI0417406A BRPI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A
- Authority
- BR
- Brazil
- Prior art keywords
- igf
- antibodies
- receptor
- cancer
- derivatized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
"ANTICORPO DO RECEPTOR ANTI-IGF-I". A presente invenção refere-se a anticorpos, anticorpos humanizados, anticorpos recondicionados, fragmentos de anticorpo, anticorpos derivatizados e conjugados dos mesmos com agente citotóxicos, que especificamente se ligam ao receptor do fator-I de crescimento equivalente à insulina e o inibem, antagonizam os efeitos de IGF-I, IGF-II e soro sobre o crescimento e sobrevivência de células de tumor e que são substancialmente destituídos de atividade agonista. Os ditos anticorpos e fragmentos destes podem ser usado, opcionalmente em conjunção com outros agentes terapêuticos, no tratamento de tumores que expressam níveis elevados de receptor de IGF-I, tais como câncer de mama, câncer de cólon, câncer pulmonar, carcinoma ovariano, sarcoma sinovial, câncer da próstata e câncer pancreático e os ditos anticorpos derivatizados podem ser usados na diagnose e formação de imagem de tumores que expressem níveis elevados de receptor de IGF-I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/729,441 US8034904B2 (en) | 2002-06-14 | 2003-12-08 | Anti-IGF-I receptor antibody |
PCT/US2004/038230 WO2005061541A1 (en) | 2002-06-14 | 2004-12-07 | Anti-igf-i receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0417406A true BRPI0417406A (pt) | 2007-04-03 |
Family
ID=36616549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417406-2A BRPI0417406A (pt) | 2003-12-08 | 2004-12-07 | anticorpo do receptor anti-igf-i |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1692176A4 (pt) |
JP (1) | JP2008502589A (pt) |
KR (1) | KR20070001883A (pt) |
CN (1) | CN1886424A (pt) |
AU (1) | AU2004303792A1 (pt) |
BR (1) | BRPI0417406A (pt) |
CA (1) | CA2548065A1 (pt) |
CR (1) | CR8426A (pt) |
EA (1) | EA009807B1 (pt) |
EC (1) | ECSP066595A (pt) |
IL (1) | IL174770A0 (pt) |
MX (1) | MXPA06005540A (pt) |
NO (1) | NO20063155L (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX361668B (es) | 2009-12-21 | 2018-12-11 | Genentech Inc | Formulación de anticuerpos. |
AU2011253101A1 (en) * | 2010-05-11 | 2013-01-10 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
EP2766478A4 (en) | 2011-10-10 | 2015-06-17 | Los Angeles Childrens Hospital | NEW ASPARAGINASE AND METHOD FOR THE TREATMENT OF DISEASES RELATED TO ASPARAGINE DEPENDENCE |
CN103509117B (zh) * | 2013-05-06 | 2016-03-09 | 江苏匡亚生物医药科技有限公司 | 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途 |
WO2018221521A1 (ja) * | 2017-05-30 | 2018-12-06 | 帝人ファーマ株式会社 | 抗igf-i受容体抗体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2351452A1 (en) * | 1998-12-04 | 2000-06-15 | Novartis Ag | Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3 |
NZ569856A (en) * | 2001-01-05 | 2010-03-26 | Pfizer | Antibodies to insulin-like growth factor 1 receptor |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
PL378812A1 (pl) * | 2003-02-13 | 2006-05-29 | Pfizer Products Inc. | Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I |
-
2004
- 2004-12-07 MX MXPA06005540A patent/MXPA06005540A/es active IP Right Grant
- 2004-12-07 CA CA002548065A patent/CA2548065A1/en not_active Abandoned
- 2004-12-07 EA EA200600931A patent/EA009807B1/ru not_active IP Right Cessation
- 2004-12-07 BR BRPI0417406-2A patent/BRPI0417406A/pt not_active IP Right Cessation
- 2004-12-07 KR KR1020067010010A patent/KR20070001883A/ko not_active Application Discontinuation
- 2004-12-07 AU AU2004303792A patent/AU2004303792A1/en not_active Abandoned
- 2004-12-07 EP EP04811082A patent/EP1692176A4/en not_active Ceased
- 2004-12-07 JP JP2006543832A patent/JP2008502589A/ja active Pending
- 2004-12-07 CN CNA200480034889XA patent/CN1886424A/zh active Pending
-
2006
- 2006-04-04 IL IL174770A patent/IL174770A0/en unknown
- 2006-05-31 EC EC2006006595A patent/ECSP066595A/es unknown
- 2006-06-01 CR CR8426A patent/CR8426A/es not_active Application Discontinuation
- 2006-07-07 NO NO20063155A patent/NO20063155L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06005540A (es) | 2006-08-17 |
AU2004303792A1 (en) | 2005-07-07 |
CA2548065A1 (en) | 2005-07-07 |
JP2008502589A (ja) | 2008-01-31 |
IL174770A0 (en) | 2006-08-20 |
EA200600931A1 (ru) | 2006-10-27 |
EA009807B1 (ru) | 2008-04-28 |
NO20063155L (no) | 2006-08-11 |
EP1692176A4 (en) | 2008-11-12 |
CR8426A (es) | 2007-12-04 |
CN1886424A (zh) | 2006-12-27 |
EP1692176A1 (en) | 2006-08-23 |
KR20070001883A (ko) | 2007-01-04 |
ECSP066595A (es) | 2006-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG141243A1 (en) | Anti-igf-i receptor antibody | |
Prendergast et al. | Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity | |
Ohno et al. | Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy | |
CA2311409A1 (en) | Treatment with anti-erbb2 antibodies | |
TN2009000007A1 (en) | Antagonist antibody against epha2 for the treatment of cancer | |
Jelovac et al. | The adjuvant treatment of HER2-positive breast cancer | |
EA032908B1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
WO2005094348A3 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
WO2007149948A3 (en) | Compositions and methods for diagnosis and treatment of tumors | |
Ju et al. | Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer | |
Kareem et al. | Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF | |
Abu-Yousif et al. | Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts | |
BRPI0417406A (pt) | anticorpo do receptor anti-igf-i | |
Ahmed et al. | The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon | |
WO2007107774A3 (en) | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer | |
Luca et al. | Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives | |
DE69829001D1 (de) | Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 | |
Ruchala et al. | Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving. | |
Jung et al. | Clathrin light chain‐conjugated drug delivery for cancer | |
Olson et al. | HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer | |
Nilsson et al. | Different toxicity profiles for drug-versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model | |
Barrott et al. | Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells | |
Aryal et al. | Immunohistoochemical evaluation of GATA-3, pAKT and Ki-67 in triple negative breast carcinoma | |
Sun et al. | Abstract B195: Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. | |
TH125460A (th) | แอนทาโกนิสต์แอนติบอดีสำหรับการรักษามะเร็ง |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: IMMUNOGEN, INC. (US) Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014. |